On August 31, 2017, the pharmaceutical industry ushered in a big news! Novartis announced that FDA has approved kymriah (tisagenlecleucel, formerly known as ctl019) as a breakthrough car-t therapy for patients under 25 years old with refractory B-cell precursor acute lymphoblastic leukemia (all) or relapse for two or more times, according to Novartis. It is worth mentioning that this is the first car-t therapy approved in human history, and the first gene therapy approved by FDA in the United States!